Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Most common treatment-emergent adverse events (occurred in ≥ 25% of all patients)Preferred termsAll patients (N = 12)Any graden (%)Grade ≥ 3n (%)Any treatment-emergent adverse event12 (100)3 (25.0) Hyperphosphataemia12 (100)0 Hyponatraemia8 (66.7)1 (8.3) Hypoalbuminaemia6 (50.0) Decreased appetite6 (50.0) Anaemia6 (50.0) Low density lipoprotein increased5 (41.7)0 Blood alkaline phosphatase increased5 (41.7)0 Hypochloraemia4 (33.3)0 Gamma-glutamyltransferase increased4 (33.3)1 (8.3) Weight decreased4 (33.3)0 Blood lactate dehydrogenase increased4 (33.3)0 Blood bilirubin increased4 (33.3)0 Diarrhoea4 (33.3)0 Proteinuria4 (33.3)1 (8.3) Hypophosphataemia3 (25.0)0 Hypercalcaemia3 (25.0)1 (8.3) Aspartate aminotransferase increased3 (25.0)0 White blood cell count decreased3 (25.0)0 Vitamin D decreased3 (25.0)0 Blood parathyroid hormone decreased3 (25.0)0 Blood creatinine increased3 (25.0)0 Nausea3 (25.0)0 Abdominal pain3 (25.0)0 Asthenia3 (25.0)0 Alopecia3 (25.0)0Adverse events were classified according to Medical Dictionary for Regulatory Activities and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0.

Source: Safety. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Open-label reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

This was a single-arm, phase I, open-label study conducted at two participating hospitals in China (ClinicalTrials.gov identifier: ), which aimed to evaluate PK/PD characteristics, and preliminary safety and antitumor activity of pemigatinib in Chinese patients with FGF/FGFR1-3 altered, advanced solid tumors.

Source: Methods.

Patients were ≥ 18 years old with unresectable advanced, recurrent or metastatic solid tumor bearing documented FGF/FGFR alterations, and had failed to prior therapy or no standard therapy available.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1 to 3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trial

Study design awaiting verification · Investigational New Drugs · 2023

Original publication title

Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1 to 3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trial

Ting Deng; Le Zhang; Yehui Shi; Guiying Bai; Yueyin Pan; Aizong Shen; Xinghua Han; Zhaoyi Yang; Mingxia Chen; Hui Zhou; Yang Luo; Shirui Zheng; Yi Ba

© The Author(s) 2023

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Pemigatinib is a selective fibroblast growth factor receptor (FGFR)1 to 3 inhibitor and has demonstrated acceptable tolerability and clinical activity in advanced solid tumors in Western population. This phase I trial evaluated pharmacokinetics/pharmacodynamics (PK/PD) characteristics, preliminary safety and efficacy of pemigatinib in Chinese patients with advanced, solid tumors. Patients with unresectable advanced or metastatic solid tumors bearing FGF/FGFR1-3 alterations received oral pemigatinib at 13.5 mg once daily (QD) on a 2-weeks-on/1-week-off schedule. The primary endpoint was PK/PD characteristics; secondary endpoints were safety and efficacy.

Twelve patients were enrolled (median age: 61 years, 58.3% males). PK data demonstrated pemigatinib (13.5 mg QD) was rapidly absorbed with a geometric mean elimination half-life of 11.3 h. The geometric mean values of maximum serum concentration and area under the plasma concentration: time curve from 0 to 24 h at steady state were 215.1 nmol/L and 2636.9 h·nmol/L, respectively. The mean clearance adjusted by bioavailability at steady state was low (11.8 L/h), and the apparent oral volume of distribution was moderate (170.5 L).

The PD marker, serum phosphate level, increased on days 8 and 15 of cycle 1 (mean: 2.25 mg/dL, CV% [percent coefficient of variation]: 31.3%) and decreased to baseline post 1 week off. Three (25.0%) patients experienced grade ≥ 3 treatment-emergent adverse events. Partial response was confirmed in one patient with FGFR1-mutant esophageal carcinoma and one with FGFR2-mutant cholagiocarcinoma. Pemigatinib had similar PK/PD characteristics to Western population and demonstrated an acceptable safety profile and potential anti-cancer benefit in Chinese patients with FGF/FGFR1-3 altered, advanced, solid tumor. (ClinicalTrials.gov: NCT04258527 [prospectively registered February 6, 2020]).

Supplementary Information

The online version contains supplementary material available at 10.1007/s10637-023-01396-x.

Authors’ abstract

Pemigatinib is a selective fibroblast growth factor receptor (FGFR)1 to 3 inhibitor and has demonstrated acceptable tolerability and clinical activity in advanced solid tumors in Western population. This phase I trial evaluated pharmacokinetics/pharmacodynamics (PK/PD) characteristics, preliminary safety and efficacy of pemigatinib in Chinese patients with advanced, solid tumors. Patients with unresectable advanced or metastatic solid tumors bearing FGF/FGFR1-3 alterations received oral pemigatinib at 13.5 mg once daily (QD) on a 2-weeks-on/1-week-off schedule. The primary endpoint was PK/PD characteristics; secondary endpoints were safety and efficacy.

Twelve patients were enrolled (median age: 61 years, 58.3% males). PK data demonstrated pemigatinib (13.5 mg QD) was rapidly absorbed with a geometric mean elimination half-life of 11.3 h. The geometric mean values of maximum serum concentration and area under the plasma concentration: time curve from 0 to 24 h at steady state were 215.1 nmol/L and 2636.9 h·nmol/L, respectively. The mean clearance adjusted by bioavailability at steady state was low (11.8 L/h), and the apparent oral volume of distribution was moderate (170.5 L).

The PD marker, serum phosphate level, increased on days 8 and 15 of cycle 1 (mean: 2.25 mg/dL, CV% [percent coefficient of variation]: 31.3%) and decreased to baseline post 1 week off. Three (25.0%) patients experienced grade ≥ 3 treatment-emergent adverse events. Partial response was confirmed in one patient with FGFR1-mutant esophageal carcinoma and one with FGFR2-mutant cholagiocarcinoma. Pemigatinib had similar PK/PD characteristics to Western population and demonstrated an acceptable safety profile and potential anti-cancer benefit in Chinese patients with FGF/FGFR1-3 altered, advanced, solid tumor. (ClinicalTrials.gov: NCT04258527 [prospectively registered February 6, 2020]).

Supplementary Information

The online version contains supplementary material available at 10.1007/s10637-023-01396-x.

Publication and source details

Original title: Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1 to 3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trial

Ting Deng; Le Zhang; Yehui Shi; Guiying Bai; Yueyin Pan; Aizong Shen; Xinghua Han; Zhaoyi Yang; Mingxia Chen; Hui Zhou; Yang Luo; Shirui Zheng; Yi Ba

Investigational New Drugs · 2023

© The Author(s) 2023https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T15:20:35.522290+00:00

DOI: 10.1007/s10637-023-01396-x · PMC10663244